PT - JOURNAL ARTICLE AU - Kjell Arne Johansson AU - Jan-Magnus Økland AU - Eirin Krüger Skaftun AU - Gene Bukhman AU - Ole Frithjof Norheim AU - Matthew M. Coates AU - Øystein Ariansen Haaland TI - Measuring Baseline Health with Individual Health-Adjusted Life Expectancy (iHALE) AID - 10.1101/19003814 DP - 2019 Jan 01 TA - medRxiv PG - 19003814 4099 - http://medrxiv.org/content/early/2019/08/15/19003814.short 4100 - http://medrxiv.org/content/early/2019/08/15/19003814.full AB - Objectives At any point of time, a person’s baseline health is the number of healthy life years they are expected to experience during the course of their lifetime. In this article we propose an equity-relevant health metric, illness-specific individual Health Adjusted Life Expectancy (iHALE), that facilitates comparison of baseline health for individuals at the onset of different medical conditions, and allows for the assessment of which patient groups are worse off. A method for calculating iHALE is presented, and we use this method to rank four conditions in six countries according to several criteria of “worse off” as a proof of concept.Methods iHALE measures baseline health at an individual level for specific conditions, and consists of two components: past health (before disease onset) and future expected health (after disease onset). Four conditions (acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), schizophrenia, and epilepsy) are analysed in six countries (Ethiopia, Haiti, China, Mexico, United States and Japan). Data for all countries and for all diseases in 2017 were obtained from the Global Burden of Disease Study database. In order to assess who are the worse off, we focus on four measures: the proportion of affected individuals who are expected to attain less than 20 healthy life years (T20), the 25th and 75th percentiles of healthy life years for affected individuals (Q1 and Q3, respectively), and the average iHALE across all affected individuals.Results Even in settings where average iHALE is similar for two conditions, other measures may vary. One example is AML (average iHALE=58.7, T20=2.1, Q3-Q1=15.3) and ALL (57.7, T20=4.7, Q3-Q1=21.8) in the US. Many illnesses, such as epilepsy, are associated with higher baseline health in high-income settings (average iHALE in Japan=64.3) than in low-income settings (average iHALE in Ethiopia=36.8).Conclusion iHALE allows for the estimation of the distribution of baseline health of all individuals in a population. Hence, baseline health can be incorporated as an equity consideration in setting priorities for health interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBill & Melinda Gates Foundation through the Disease Control Priorities Ethiopia (DCP-Ethiopia) project grant [OPP1162384] to the University of Bergen and Harvard T.H. Chan School of Public Health.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe data used to create the tables and figures in this paper can be accessed without restrictions at https://doi.org/10.5281/zenodo.3258330. https://doi.org/10.5281/zenodo.3258330 (iHALE)individual Health Adjusted Life Expectancy(iLE)individual life expectancy(PIM)Period of Increased Mortality(PID)Period of Increased Disability(HAA)health adjusted age(CEA)cost-effectiveness analysis(GBD)Global Burden of Diseases(DALY)disability-adjusted life-years(HALY)healthy life years(YLL)years of life lost(YLD)years lived with disability(AML)acute myeloid leukemia(ALL)acute lymphoid leukemia